How long is the survival period of nasopharyngeal carcinoma metastasized to the lungs and what to do

Nasopharyngeal carcinoma is one of the most common diseases in China. It seriously threatens our health and should be treated in time. So, how long is the survival time of nasopharyngeal carcinoma metastases to the lungs? What should be done?

How long is the survival period of nasopharyngeal carcinoma metastasized to the lungs? When nasopharyngeal carcinoma metastasizes to the lungs, the disease progresses seriously. How long can a nasopharyngeal carcinoma patient with lung metastasis live varies from person to person. Most patients with nasopharyngeal carcinoma are in the middle and late stages, and about 60% of them will have symptoms of recurrence and metastasis within 3 years after treatment. Combining Western medicine treatment with ginsenoside RH2 can improve efficiency, reduce toxicity, shorten the healing cycle, and prevent recurrence and metastasis. The current survival period of nasopharyngeal carcinoma is relatively good. The prognosis requires more follow-up examinations and attention to daily life rules, especially dietary rules.

Once nasopharyngeal carcinoma metastasizes to the lungs, it means it has reached an advanced stage. The main treatment methods are as follows:

First: Radiotherapy is one of the main methods for treating nasopharyngeal carcinoma. External radiation can be performed in a continuous or segmented manner. Although the long-term efficacy of these two methods is similar, the total time of the former is shorter and the reaction after radiotherapy is more severe; the total radiotherapy time of the latter is longer, but the reaction after radiotherapy is milder. Appropriate selection should be made according to the specific situation of the patient.

Second: combined chemotherapy: Combination chemotherapy is often used for mid-term chemotherapy of nasopharyngeal carcinoma, and its effect is better than single-drug chemotherapy. It is usually used in combination with mid-term radiotherapy of nasopharyngeal carcinoma, which has good short-term efficacy, but little benefit for long-term treatment.

Third: Cell immunotherapy: Patients with mid-stage nasopharyngeal carcinoma generally have poor physical fitness, and cell immunotherapy is often used clinically. Cell immunotherapy has the dual effects of improving the body's immunity and killing cancer cells. It can be used for auxiliary treatment of mid-stage radiotherapy and chemotherapy for nasopharyngeal carcinoma, improve patients' adverse symptoms, effectively treat mid-stage spread and metastasis of nasopharyngeal carcinoma, improve quality of life and prolong their survival.